Our observations have substantial consequences in our thinking of IBD and open the possibility that by targeting PXR signaling therapeutic benefit may be achieved, especially in those patients with epithelial hyper-activation of NF-κB signaling. Here, NFKB1 is linked to inflammatory bowel disease.